围手术期磷霉素二钠预防肾移植受者尿路感染:随机临床试验
肾移植受者围手术期在留置和拔除导尿管及拔除双J管前静脉给予单剂4g磷霉素二钠,与安慰剂对照,所有参与者均接受复方新诺明预防。7周随访期间磷霉素组每患者无症状菌尿或症状性尿路感染平均发作次数较低(意向性分析0.29 vs 0.60,P=0.04),症状性尿路感染发生率较低(7.3% vs 36.6%,P=0.001),无症状菌尿发生率无差异,不良事件发生率相似。
要点
- 围手术期单剂4g静脉磷霉素可降低肾移植后7周内症状性尿路感染发生率。
- 磷霉素组症状性尿路感染发生率7.3%,安慰剂组36.6%,差异有统计学意义。
- 两组无症状菌尿发生率及不良事件发生率无差异。
核心结论
- 围手术期加用磷霉素二钠是减少肾移植后最初7周内症状性尿路感染次数的有效且安全策略。
研究设计与样本
- 干预为在留置和拔除导尿管前及拔除双J输尿管支架前静脉给予单剂4g磷霉素二钠或安慰剂,所有参与者均接受复方新诺明预防。
- 主要结局为7周随访期间每患者症状性尿路感染和无症状菌尿平均发作次数的比较。
- 研究注册于ClinicalTrials.gov,注册号NTC03235947。
主要发现
- 意向性分析中,磷霉素组每患者无症状菌尿或症状性尿路感染平均发作次数为0.29,安慰剂组为0.60,P=0.04。
- 意向性分析中,磷霉素组症状性尿路感染发生率为7.3%,安慰剂组为36.6%,P=0.001。
- 两组无症状菌尿发生率无差异。
- 两组不良事件发生率相似。
临床怎么用
- 对于接受复方新诺明预防的肾移植受者,围手术期可考虑加用单剂4g静脉磷霉素二钠以降低早期症状性尿路感染风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Symptomatic urinary tract infection (UTI) is the most common infectious complication in renal transplant recipients (RTRs). Fosfomycin (FOS) is an attractive alternative for prophylaxis because it does not interact with immunosuppressants; although 90% is excreted unchanged in the urine, it does not require adjustment for renal function for single dose prophylaxis. METHODS: RTRs were recruited into this randomized, double-blind, placebo-controlled trial. Participants were randomized (1:1) to receive one 4 g dose of FOS disodium intravenously 3 h (FOS group) or placebo (placebo group) before placement and removal of a urinary catheter and before removal of a double-J ureteral stent. All participants received prophylaxis with trimethoprim/sulfamethoxazole. The main outcome was a comparison of the mean number of symptomatic UTI and asymptomatic bacteriuria (AB) episodes per patient during a 7-week follow-up period. The study was registered at ClinicalTrials.gov, NTC03235947. RESULTS: Eighty-two participants were included (41 in the FOS group and 41 in placebo group). The mean number of AB or symptomatic UTI episodes per patient was lower in the FOS group [intention-to-treat (ITT) 0.29 versus 0.60, P = 0.04]. The incidence of symptomatic UTI was lower in the FOS group (ITT, 7.3% versus 36.6%, P = 0.001), and there was no difference in the incidence of AB between both groups. The incidence of adverse events was similar in both groups. CONCLUSIONS: FOS addition is an effective and safe strategy to reduce the number of symptomatic UTIs during the first 7 weeks after renal transplant.
引用
- Rosado-Canto R, Parra-Avila I, Tejeda-Maldonado J, et al. Perioperative fosfomycin disodium prophylaxis against urinary tract infection in renal transplant recipients: a randomized clinical trial. Nephrol Dial Transplant. 2020. PMID: 31883327. doi:10.1093/ndt/gfz261
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。